HK1159628A1 - 作為激酶的抑制劑用於治療癌症的噻吩並 吡啶衍生物 - Google Patents

作為激酶的抑制劑用於治療癌症的噻吩並 吡啶衍生物

Info

Publication number
HK1159628A1
HK1159628A1 HK12100183.3A HK12100183A HK1159628A1 HK 1159628 A1 HK1159628 A1 HK 1159628A1 HK 12100183 A HK12100183 A HK 12100183A HK 1159628 A1 HK1159628 A1 HK 1159628A1
Authority
HK
Hong Kong
Prior art keywords
thieno
cancer
treatment
kinase inhibitors
pyridine derivatives
Prior art date
Application number
HK12100183.3A
Other languages
English (en)
Inventor
Michael R Michaelides
Robin R Frey
Michael L Curtin
Original Assignee
Abbvie Bahamas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Bahamas Ltd filed Critical Abbvie Bahamas Ltd
Publication of HK1159628A1 publication Critical patent/HK1159628A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK12100183.3A 2008-12-05 2012-01-06 作為激酶的抑制劑用於治療癌症的噻吩並 吡啶衍生物 HK1159628A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12028108P 2008-12-05 2008-12-05
US22376009P 2009-07-08 2009-07-08
PCT/US2009/066725 WO2010065825A2 (en) 2008-12-05 2009-12-04 Kinase inhibitors with improved cyp safety profile

Publications (1)

Publication Number Publication Date
HK1159628A1 true HK1159628A1 (zh) 2012-08-03

Family

ID=41559043

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12100183.3A HK1159628A1 (zh) 2008-12-05 2012-01-06 作為激酶的抑制劑用於治療癌症的噻吩並 吡啶衍生物

Country Status (26)

Country Link
US (2) US20100144783A1 (zh)
EP (1) EP2373662B1 (zh)
JP (1) JP5588458B2 (zh)
KR (1) KR101639642B1 (zh)
CN (1) CN102239171B (zh)
AR (1) AR074481A1 (zh)
AU (1) AU2009322270B2 (zh)
BR (1) BRPI0921392A2 (zh)
CA (1) CA2743592A1 (zh)
CL (1) CL2011001312A1 (zh)
CO (1) CO6382131A2 (zh)
DO (1) DOP2011000153A (zh)
EC (1) ECSP11011172A (zh)
ES (1) ES2524966T3 (zh)
HK (1) HK1159628A1 (zh)
IL (1) IL212716A (zh)
MX (1) MX2011005943A (zh)
MY (1) MY179042A (zh)
NZ (1) NZ592714A (zh)
PA (1) PA8852401A1 (zh)
PE (1) PE20110830A1 (zh)
RU (2) RU2480472C2 (zh)
TW (2) TWI441827B (zh)
UA (1) UA103351C2 (zh)
UY (1) UY32291A (zh)
WO (1) WO2010065825A2 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7202363B2 (en) * 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
JP5588458B2 (ja) * 2008-12-05 2014-09-10 アッヴィ・バハマズ・リミテッド 癌の治療に使用するためのキナーゼ阻害剤としてのチエノ［３，２−ｃ］ピリジン誘導体
TWI492949B (zh) 2010-06-09 2015-07-21 Abbvie Bahamas Ltd 結晶型激酶抑制劑
CA2802042A1 (en) 2010-06-09 2011-12-15 Abbott Laboratories Crystalline forms of kinase inhibitors
TWI482770B (zh) 2010-06-09 2015-05-01 Abbvie Bahamas Ltd 結晶型激酶抑制劑
MX2012014387A (es) 2010-06-09 2013-05-01 Abbvie Inc Dispersiones solidas que contienen inhibidores de cinasa.
US8911725B2 (en) 2010-06-23 2014-12-16 University Of Central Florida Research Foundation, Inc. Co-targeting of aurora A kinase and LIM kinase 1 for cancer therapy
WO2013012909A1 (en) 2011-07-20 2013-01-24 Abbott Laboratories Kinase inhibitor with improved aqueous solubility
JP2015500343A (ja) * 2011-12-14 2015-01-05 アッヴィ・インコーポレイテッド キナーゼ阻害剤を含有する組成物
AU2013302319A1 (en) * 2012-08-17 2015-02-26 Cancer Therapeutics Crc Pty Limited VEGFR3 inhibitors
US9238644B2 (en) * 2012-08-17 2016-01-19 Cancer Therapeutics Crc Pty Limited VEGFR3 inhibitors
CN103012428A (zh) * 2013-01-08 2013-04-03 中国药科大学 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途
WO2015157360A1 (en) 2014-04-08 2015-10-15 Abbvie Inc. Processes to make protein kinase inhibitors
US20170197980A1 (en) * 2014-06-25 2017-07-13 Abbvie Inc. N-(4-phenyl)-n'-(3-fluorophenyl)urea docusate
JPWO2020130125A1 (ja) 2018-12-21 2021-11-04 第一三共株式会社 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
WO2020252353A1 (en) * 2019-06-12 2020-12-17 Vanderbilt University Amino acid transport inhibitors and the uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1188529A (en) 1966-06-09 1970-04-15 Wellcome Found Pyramidine Derivatives
US4357535A (en) 1980-04-30 1982-11-02 North American Philips Corporation Apparatus for inspecting hand-held articles and persons carrying same
GB8307154D0 (en) 1983-03-15 1983-04-20 Mk Electric Ltd Terminals
US4767766A (en) 1987-01-30 1988-08-30 Merck & Co., Inc. Derivatives of 3-hydroxyazabenzo(B)thiophene useful as 5-lipoxygenase inhibitors
EP0300688A1 (en) 1987-07-21 1989-01-25 FISONS plc Pyrrole derivatives, process for their preparation and pharmaceutical compositions containing them
JPH0436810Y2 (zh) 1987-12-29 1992-08-31
US4843949A (en) 1988-08-29 1989-07-04 Pneumo Abex Corporation Fluid control valve with variable pressure gain
GB8912498D0 (en) 1989-05-31 1989-07-19 De Beers Ind Diamond Diamond growth
EP0438261A3 (en) 1990-01-16 1992-02-26 Takeda Chemical Industries, Ltd. Condensed heterocyclic glutamic acid derivatives, their production and use
DE4129603A1 (de) 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
EP0630031B1 (en) 1993-06-16 2002-08-14 E.I. Du Pont De Nemours And Company Water cleanable thick film paste composition
IL112759A0 (en) 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
DE29511756U1 (de) 1995-07-20 1995-09-28 Ferco International Usine de Ferrures de Bâtiment S.A.R.L., Sarrebourg Flügelseitiges Ecklagerbeschlagteil für Drehkippfenster
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
DE19620508A1 (de) 1996-05-22 1997-11-27 Hoechst Ag Schwefelenthaltende heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung
NZ337976A (en) 1997-04-22 2001-05-25 Neurosearch As Substituted phenyl derivatives, their preparation and use
ID27124A (id) 1997-10-20 2001-03-01 Hoffmann La Roche Penghambat kinase bisiklik
WO2000039102A1 (en) 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company THROMBIN OR FACTOR Xa INHIBITORS
TR200201506T2 (tr) 1999-09-17 2002-10-21 Abbott Gmbh & Co. Kg Terapötik maddeler olarak kinaz inhibitörleri
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
US20020004511A1 (en) 2000-06-28 2002-01-10 Luzzio Michael Joseph Thiophene derivatives useful as anticancer agents
US7447791B2 (en) 2000-12-15 2008-11-04 British Telecommunications Public Limited Company Transmission and reception of audio and/or video material
US7348359B2 (en) 2001-03-14 2008-03-25 Eli Lilly And Company Retinoid X receptor modulators
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
JP2005508904A (ja) 2001-09-11 2005-04-07 スミスクライン ビーチャム コーポレーション 血管新生阻害剤としてのフロ−及びチエノピリミジン誘導体
MXPA04005561A (es) 2001-12-21 2004-12-06 Bayer Pharmaceuticals Corp Terapias de combinacion anti-angiogenesis que comprenden derivados de piridazina o piridina.
WO2004064778A2 (en) 2003-01-17 2004-08-05 Merck & Co. Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
DE10303311A1 (de) * 2003-01-28 2004-07-29 Basf Ag Addukte auf Basis cyclischer Verbindungen und ihre Verwendung als Gerbstoffe und Konservierungsmittel
WO2004100947A2 (en) 2003-05-06 2004-11-25 Smithkline Beecham Corporation Novel chemical compounds
US7202363B2 (en) * 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
US20050026944A1 (en) * 2003-07-24 2005-02-03 Patrick Betschmann Thienopyridine and furopyridine kinase inhibitors
US7419978B2 (en) 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
JP2008519862A (ja) 2004-11-11 2008-06-12 アキリオン ファーマシューティカルズ，インコーポレーテッド Ｈｉｖ−１カプシド形成のインヒビター：置換アリール・アミノメチル・チアゾール尿素およびその類縁物質
US7790729B2 (en) 2005-05-20 2010-09-07 Methylgene Inc. Inhibitors of VEGF receptor and HGF receptor signaling
US7566721B2 (en) 2005-08-08 2009-07-28 Osi Pharmaceuticals, Inc. Substituted thienol[2,3-d]pyrimidines as kinase inhibitors
CA2619462A1 (en) 2005-08-16 2007-02-22 Amgen, Inc. Phosphodiesterase 10 inhibitors
EP1951728A4 (en) 2005-11-04 2011-04-20 Glaxosmithkline Llc THIENOPYRIDINES AS INHIBITORS OF B-RAF KINASE
CN101336244B (zh) * 2005-12-08 2011-11-30 雅培制药有限公司 用作蛋白激酶抑制剂的9元杂二环化合物
AU2007275221A1 (en) 2006-07-20 2008-01-24 Allen J. Borchardt Benzothiophene inhibitors of RHO kinase
JP5588458B2 (ja) * 2008-12-05 2014-09-10 アッヴィ・バハマズ・リミテッド 癌の治療に使用するためのキナーゼ阻害剤としてのチエノ［３，２−ｃ］ピリジン誘導体

Also Published As

Publication number Publication date
ES2524966T3 (es) 2014-12-16
CN102239171B (zh) 2014-06-11
ECSP11011172A (es) 2011-08-31
AU2009322270B2 (en) 2014-12-18
RU2480472C2 (ru) 2013-04-27
CN102239171A (zh) 2011-11-09
AR074481A1 (es) 2011-01-19
JP5588458B2 (ja) 2014-09-10
EP2373662A2 (en) 2011-10-12
BRPI0921392A2 (pt) 2016-04-26
WO2010065825A2 (en) 2010-06-10
MY179042A (en) 2020-10-26
MX2011005943A (es) 2011-06-27
TWI500621B (zh) 2015-09-21
TW201026706A (en) 2010-07-16
CO6382131A2 (es) 2012-02-15
US8722890B2 (en) 2014-05-13
RU2011127451A (ru) 2013-01-10
AU2009322270A1 (en) 2011-07-14
WO2010065825A3 (en) 2010-08-26
PA8852401A1 (es) 2010-07-27
CL2011001312A1 (es) 2011-10-07
EP2373662B1 (en) 2014-09-24
TW201431862A (zh) 2014-08-16
KR101639642B1 (ko) 2016-07-14
DOP2011000153A (es) 2011-06-30
IL212716A0 (en) 2011-07-31
KR20110091577A (ko) 2011-08-11
CA2743592A1 (en) 2010-06-10
US20120309783A1 (en) 2012-12-06
TWI441827B (zh) 2014-06-21
NZ592714A (en) 2013-03-28
UA103351C2 (uk) 2013-10-10
IL212716A (en) 2013-10-31
US20100144783A1 (en) 2010-06-10
JP2012511016A (ja) 2012-05-17
RU2012156958A (ru) 2014-06-27
UY32291A (es) 2010-07-30
PE20110830A1 (es) 2011-12-14

Similar Documents

Publication Publication Date Title
HK1159628A1 (zh) 作為激酶的抑制劑用於治療癌症的噻吩並 吡啶衍生物
PL2419428T3 (pl) Pochodne imidazo[1,2-A]pirydyny jako inhibitory kinaz FGFR do zastosowania w terapii
ZA201106599B (en) Pyrrolo [2,3-b] pyridine derivatives for the inhibition of raf kinases
IL199323A (en) Converted Pirazolo-Quinazoline History, Process for Preparation and Use as Kinase Inhibitors
AP2939A (en) Thieno [2,3-B] pyridine derivatives as viral replication inhibitors
EP2235004A4 (en) INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL-SUBSTITUTED INDOLUND DERIVATIVES AS A KINASE-HEMMER FOR CANCER TREATMENT
IL195731A0 (en) Pyrimidine derivatives useful in the treatment of cancer
HK1148284A1 (zh) 用於治療 介導的症狀的異噁唑吡啶衍生物
HK1153926A1 (zh) 用於治療 -相關疾病的嘌呤衍生物
ZA201000075B (en) Purin derivatives for use in the treatment of fab-related diseases
ZA201000085B (en) 2-oxo-3-benzyl-benzoxazol-2-one derivatives and related compounds as Met kinase inhibitors for the treatment of tumors
IL194755A0 (en) Pyrimidine derivatives as pi3k inhibitors
PT2120932E (pt) Derivados de indazol como inibidores da quinase para tratamento do cancro
IL219424A0 (en) IMIDAZO [1,2-b] PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
IL211825A0 (en) Pyridine and pyrimidine based compounds as wnt sigaling pathway inhibitors for the treatment of cancer
IL217798A0 (en) Pyrrolo [1,2-b]pyridazine derivatives as janus kinase inhibitors
EP2331520A4 (en) ROSAMINE DERIVATIVES AS AGENTS FOR CANCER TREATMENT
PL2188289T3 (pl) (7H-pirolo[2,3-D]pirymidyn-4-ylo)-piperazyny jako inhibitory kinaz do leczenia nowotworów i zapalenia
ZA201005554B (en) Furo-and thieno[3,2-c]pyridines
LT2229369T (lt) 6,7-dialkoksi-chinazolino dariniai, tinkami panaudoti su vėžiu susijusių susirgimų gydymui
ZA200906648B (en) Pyrido [2,3-D] pyramidin-7-one compounds as inhibitors of P13K-alpha for the treatment of cancer
PL2124944T3 (pl) Pochodne pirazolo[3,4-b]pirydyny jako inhibitory fosfodiesterazy
IL214426A0 (en) [1,2,4] triazollo [1,5-a] pyridines as kinase inhibitors
IL209840A0 (en) Azacarboline derivatives, preparation thereof, and therapeutic use thereof as kinase inhibitors
HK1139948A1 (en) Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer